Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17549
Country/Region: Lesotho
Year: 2018
Main Partner: Johns Hopkins University
Main Partner Program: JHPIEGO
Organizational Type: University
Funding Agency: USAID
Total Funding: $7,077,418 Additional Pipeline Funding: $648,328

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $5,169,914
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Prevention: HIV Testing and Counseling (HVCT) $0
Sexual Prevention: Other Sexual Prevention (HVOP) $1,907,504
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $0
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTC_TST_DSD HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Negative 2019 3,549
HTC_TST_DSD HTS_TST_N_DSD_VMMC_Age_Sex_Result 25-29, Male, Positive 2019 74
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 36,279
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 10-14, Negative 2019 14,196
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 10-14, Positive 2019 291
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 15-19, Negative 2019 10,647
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 15-19, Positive 2019 218
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 20-24, Negative 2019 7,100
HTC_TST_DSD Service Delivery Point (Facility) VMMC: 20-24, Positive 2019 144
HTS_SELF_DSD HTS_SELF_N_DSD 2019 860
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Female, Directly-Assisted 2019 8
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 10-14, Male, Directly-Assisted 2019 8
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted 2019 55
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted 2019 12
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted 2019 40
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted 2019 16
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted 2019 94
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted 2019 21
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted 2019 65
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted 2019 14
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted 2019 43
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted 2019 15
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted 2019 58
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted 2019 17
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted 2019 43
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted 2019 15
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted 2019 52
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted 2019 17
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted 2019 41
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted 2019 8
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted 2019 52
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted 2019 15
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted 2019 41
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted 2019 8
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted 2019 54
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted 2019 15
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted 2019 16
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted 2019 2
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted 2019 13
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted 2019 2
HTS_SELF_DSD HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted 2019 683
HTS_SELF_DSD HTS_SELF_N_DSD_HIVSelfTest Unassisted 2019 177
HTS_SELF_DSD HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Self 2019 166
HTS_SELF_DSD HTS_SELF_N_DSD_HIVSelfTestUser Unassisted - Sex Partner 2019 11
PrEP_NEW_DSD Female 15-19 2019 608
PrEP_NEW_DSD Female 20-24 2019 634
PrEP_NEW_DSD Female 50+ 2019 843
PrEP_NEW_DSD FSW 2019 513
PrEP_NEW_DSD Male 15-19 2019 390
PrEP_NEW_DSD Male 20-24 2019 393
PrEP_NEW_DSD Male 50+ 2019 511
PrEP_NEW_DSD MSM 2019 1,043
PrEP_NEW_DSD Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 6,808
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Female 2019 547
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 25-29, Male 2019 330
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Female 2019 506
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 30-34, Male 2019 359
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Female 2019 476
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 35-39, Male 2019 366
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Female 2019 476
PrEP_NEW_DSD PrEP_NEW_N_DSD_Age_Sex_v2 40-49, Male 2019 369
PrEP_NEW_DSD PrEP_NEW_N_DSD_KeyPopAbr Other Key Populations 2019 20
VMMC_CIRC_DSD By Age: 10-14 2019 14,488
VMMC_CIRC_DSD By Age: 15-19 2019 10,865
VMMC_CIRC_DSD By Age: 20-24 2019 7,244
VMMC_CIRC_DSD By Age: 25-29 2019 3,622
VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 2019 179
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 2019 36,040
VMMC_CIRC_DSD Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2019 36,219
VMMC_CIRC_DSD Sum of age disaggregates (FY15-Current) 2019 36,219
VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 2019 32,597
Cross Cutting Budget Categories and Known Amounts Total: $1,729,736
Gender: Gender Based Violence (GBV) $5,000
GBV Prevention
Adolescent Girls and Young Women (AGYW) $1,724,736